Two stocks in Healthcare
Merck KGaA vs Ypsomed Holding: profit, growth, debt and price compared
Merck KGaA and Ypsomed Holding are each stronger on 3 of 7 figures: Merck KGaA on sales growth, price for its expected profit and dividend; Ypsomed Holding on profit margin, debt and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Merck KGaAMRK.DE | Ypsomed HoldingYPSN.SW | |
|---|---|---|
| Net margin | 8.9% | Stronger: 30.4% |
| Revenue growth, past year | Stronger: +5.80% | −13.30% |
| Debt to equity | 38.1% | Stronger: 34.9% |
| Forward P/E | Stronger: 16.4× | 28.8× |
| Dividend yield | Stronger: 1.47% | 1.04% |
| Analysts | Buy · 14 | Buy · 14 |
| From its 200-day average | +11.7% | Stronger: +21.2% |
Share price over the past year
- Merck KGaA+35.2%
- Ypsomed Holding+34.9%
20 Nov 202518 Nov 2026
Merck KGaA or Ypsomed Holding: which is stronger?
- YPSN.SW
Which is more profitable?
Ypsomed Holding keeps more of each sale as profit: 30.4% against 8.9%.
- MRK.DE
Which is growing its sales faster?
Merck KGaA is growing its sales faster: +5.80% over the past year, against −13.30%.
- YPSN.SW
Which has borrowed less?
Ypsomed Holding has borrowed less: its debt is 34.9% of what its shareholders own, against 38.1% for Merck KGaA.
- MRK.DE
Which costs less for the profit it is expected to make?
Merck KGaA costs less for the profit it is expected to make: 16.4× its forward earnings, against 28.8×.
- MRK.DE
Which pays more in dividends?
Merck KGaA pays more back in dividends for what a share costs: 1.47% a year, against 1.04%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- YPSN.SW
Which is in the stronger price trend?
Ypsomed Holding's price is in the stronger trend: 21.2% above its 200-day average, against 11.7% above.
What each company does
MRK.DEMerck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Reports results on 4 March 2027
YPSN.SWYpsomed Holding
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally.
Reports results on 19 May 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.